GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Profitability Rank

Cardax (Cardax) Profitability Rank : 0 (As of Mar. 2021)


View and export this data going back to 2012. Start your Free Trial

What is Cardax Profitability Rank?

Cardax has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Cardax's Operating Margin % for the quarter that ended in Mar. 2021 was -734.29%. As of today, Cardax's Piotroski F-Score is 0.


Competitive Comparison of Cardax's Profitability Rank

For the Biotechnology subindustry, Cardax's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardax's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardax's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Cardax's Profitability Rank falls into.



Cardax Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Cardax has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cardax's Operating Margin % for the quarter that ended in Mar. 2021 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2021 ) / Revenue (Q: Mar. 2021 )
=-0.771 / 0.105
=-734.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Cardax has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Cardax Profitability Rank Related Terms

Thank you for viewing the detailed overview of Cardax's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardax (Cardax) Business Description

Traded in Other Exchanges
N/A
Address
2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822
Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.
Executives
Paulson Capital Corp 10 percent owner 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc. 10 percent owner 5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc 10 percent owner 811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204

Cardax (Cardax) Headlines

From GuruFocus

Cardax Reports Q3 2018 Results

By PRNewswire PRNewswire 11-14-2018

Cardax Voluntarily Suspends SEC Reporting Obligations

By PRNewswire PRNewswire 08-11-2021

Cardax Reports 2018 Results

By PRNewswire PRNewswire 03-28-2019

Cardax Reports Q2 2018 Results

By PRNewswire PRNewswire 08-15-2018

Cardax Reports Q1 2018 Results

By PRNewswire PRNewswire 05-09-2018

Cardax Reports Q1 2021 Results

By PRNewswire PRNewswire 05-14-2021

Cardax Announces Interim Results from CHASE Clinical Trial

By PRNewswire PRNewswire 09-23-2019

Cardax Reports Q2 2020 Results

By PRNewswire PRNewswire 08-15-2020